Current Report Filing (8-k)
September 21 2020 - 8:26AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September
17, 2020
Humanigen, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-35798
|
|
77-0557236
|
(State or other Jurisdiction of
Incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
533 Airport Boulevard, Suite 400
Burlingame, CA 94010
(Address of principal executive offices, including zip
code)
(650) 243-3100
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
|
o
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
HGEN
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company o
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. o
On September 17, 2020, Humanigen, Inc. (the “Company”)
entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Jefferies
LLC, as representatives of the several underwriters, in connection with the public offering of 8,000,000 of the Company’s
shares of common stock, par value $0.001 per share. The closing of the offering is expected to occur on or about September 22,
2020. Pursuant to the Underwriting Agreement, the Company granted the underwriters a 30-day option to purchase an additional 1,200,000
shares of common stock, which option was exercised in full by the underwriters on September
18, 2020.
As a result of the pricing of
the public offering, the Company’s common stock has commenced trading on the Nasdaq Capital Market under the symbol “HGEN.”
The Company estimates that the net proceeds from the sale of
the full 9,200,000 shares in the offering, after deducting underwriting discounts and estimated offering costs, will be approximately
$72.8 million. The Company expects to use the net proceeds from the offering to support its manufacturing, production and commercial
preparation activities relating to lenzilumab as a potential therapy for COVID-19 patients and for general corporate purposes.
A copy of the Underwriting Agreement
is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The summary set forth above
is qualified in its entirety by reference to Exhibit 1.1.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Humanigen, Inc.
|
|
|
|
By:
|
/s/ Cameron Durrant
|
|
|
|
Name: Cameron Durrant
Title: Chairman of the Board and Chief Executive Officer
|
Dated: September 21, 2020
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024